Product Information
RIVASTIGMINE 9.5 MG/24HR PATCH is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.7823 per EA under NDC 00378907193. Its NADAC has been published 426 times since Aug 8, 2018.
FDA first approved this application on Jun 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
9.5 mg/24h
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378907193
Classification
Generic
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA205622FDA Approved
6/20/2018
TE Code
AB
On Market Since
6/20/2018
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 9.5 MG/24HR PATCH has been published 426 times since Aug 8, 2018, and over the history we have for it it has declined 68.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7823 per EA |
|---|---|
| All-time high | $6.2603 (Oct 10, 2018) |
| All-time low | $1.2926 (Nov 20, 2024) |
| 52-week high | $1.9231 |
| 52-week low | $1.6974 |
| Median price | $2.3279 |
| Average price | $2.9568 |
| Largest weekly change | -30.1% (Nov 20, 2024) |
| Weeks tracked | 426 |
| Tracking since | Aug 8, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rivastigmine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 9.5 MG/24HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 9.5 MG/24HR PATCH, manufactured by Mylan Pharmaceuticals Inc., is $1.7823 per EA (NDC 00378907193), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 9.5 MG/24HR PATCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 9.5 MG/24HR PATCH has declined 68.6%. It has been tracked across 426 weekly CMS publications since Aug 8, 2018.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 9.5 MG/24HR PATCH?
Since Aug 8, 2018, the NADAC for RIVASTIGMINE 9.5 MG/24HR PATCH has ranged from a low of $1.2926 (Nov 20, 2024) to a high of $6.2603 (Oct 10, 2018), with a median of $2.3279 per EA.
Are there cheaper alternatives to RIVASTIGMINE 9.5 MG/24HR PATCH?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 9.5 MG/24HR PATCH in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 9.5 MG/24HR PATCH?
RIVASTIGMINE 9.5 MG/24HR PATCH (NDC 00378907193) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.